Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shane Lipskind

Reproductive Endocrinology Scottsdale, AZ Medical Doctor

NPI 1134383698 CMS profile 51065

8426 E Shea Blvd, Scottsdale, AZ 85260

Open in the dashboard

General payments

$2,365

76 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shane Lipskind of Scottsdale, AZ is reported in the CMS Open Payments database as having received $2,365 across 76 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $430 9
2024 General $301 7
2023 General $575 27
2022 General $469 14
2021 General $164 5
2020 General $49 3
2019 General $378 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shane Lipskind
  • Reproductive Endocrinology median
  • Middle half of Reproductive Endocrinology
  • National median

In program year 2025, general payments to Shane Lipskind were reported at $430. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.

Show as a table
Year Shane Lipskind Reproductive Endocrinology median Middle half National median
2019 $378 $196 $77–$425 $163
2020 $49 $81 $35–$182 $114
2021 $164 $102 $43–$247 $132
2022 $469 $139 $62–$303 $149
2023 $575 $141 $65–$285 $160
2024 $301 $144 $65–$302 $164
2025 $430 $141 $66–$285 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organon LLC $532 19 payments
  2. CooperSurgical, Inc. $348 9 payments
  3. AbbVie, Inc. $307 3 payments
  4. Ferring Pharmaceuticals Inc. $273 23 payments
  5. Hologic, LLC $147 3 payments
  6. Becton, Dickinson and Company $130 1 payment
  7. Merck Sharp & Dohme Corporation $129 7 payments
  8. Vertex Pharmaceuticals Incorporated $120 1 payment
  9. Roche Diagnostics Corporation $106 1 payment
  10. ViiV Healthcare Company $105 1 payment
  11. Other $167 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,365 76 payments
Products named General payments · program years 2019–2025
  1. FOLLISTIM AQ Follitropin $857 27 payments
  2. PREGNYL $435 14 payments
  3. GANIRELIX ACETATE $415 13 payments
  4. STRIPPER $272 8 payments
  5. MENOPUR $168 18 payments
  6. BD Onclarity $130 1 payment
  7. FOLLISTIM AQ Womens Health $129 7 payments
  8. ACESSA PROVU SYSTEM $117 1 payment
  9. HUMIRA $110 1 payment
  10. cobas 4800 CT/NG Test v2.0 $106 1 payment
  11. Other $651 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

76 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Reproductive Endocrinology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record